Drug
Antibody-Drug Conjugate
Antibody-Drug Conjugate is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (100.0%)
Trials by Status
completed125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_1
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658
recruiting
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
NCT07051850
recruiting
Immunotherapy in Lymphoma
NCT06796517
completed
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
NCT05349383
Clinical Trials (4)
Showing 4 of 4 trials
NCT06014658Phase 1
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT07051850
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
NCT06796517
Immunotherapy in Lymphoma
NCT05349383
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4